Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 5/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4660603 | 0.81 | GPR84 (0.33) | GPR84 | |
| Monoethanolamine SCHEMBL20602874 | 0.79 | GPR84 (0.32) | GPR84 | |
| SCHEMBL4286679 | 0.72 | GPR84 (0.42) | GPR84 | |
| SCHEMBL794919 | 0.71 | PARP1 (0.31) | — | |
| SCHEMBL8884531 | 0.69 | MPO (0.53) | GPR84 | |
| Monoethanolamine SCHEMBL5374537 | 0.68 | PARP1 (0.30) | — | |
| SCHEMBL19583321 | 0.66 | MAPT (0.32) | — | |
| SCHEMBL1170468 | 0.64 | PRKCA (0.34) | GPR84 | |
| SCHEMBL6695551 | 0.63 | GPR84 (0.69) | GPR84 | |
| SCHEMBL8505208 | 0.62 | KDM4E (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030086881-A1 | Antiinfective combinations and their use for the topical treatment of fungal infections of the toenails and fingernails | AVENTIS PHARMA DEUTSCHLAND GMBH | 2003-05-08 | — | — | US | claimed |
| US-20010046478-A1 | Antiinfective combinations and their use for the topical treatment of fungal infections of the toenails and fingernails | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-11-29 | — | — | US | claimed |
| EP-0315912-B1 | SEBOSUPPRESSIVE PREPARATIONS | Henkel Kommanditgesellschaft auf Aktien (DE) | 1992-06-17 | — | — | EP | claimed |
| US-20180296459-A1 | COMPOSITIONS CONTAINING POLYMERIC, IONIC COMPOUNDS COMPRISING IMIDAZOLIUM GROUPS | BASF SE (DE) | 2018-10-18 | — | — | US | disclosed |
| EP-3378313-A1 | COMPOSITIONS CONTAINING POLYMERIC, IONIC COMPOUNDS COMPRISING IMIDAZOLIUM GROUPS | BASF SE (DE) | 2018-09-26 | — | — | EP | disclosed |
| EP-2688405-B1 | COMPOSITIONS CONTAINING POLYMERIC, IONIC COMPOUNDS COMPRISING IMIDAZOLIUM GROUPS | BASF SE (DE) | 2017-11-22 | — | — | EP | disclosed |
| EP-2688405-A1 | COMPOSITIONS CONTAINING POLYMERIC, IONIC COMPOUNDS COMPRISING IMIDAZOLIUM GROUPS | BASF SE (DE) | 2014-01-29 | — | — | EP | disclosed |
| WO-2012127009-A1 | COMPOSITIONS CONTAINING POLYMERIC, IONIC COMPOUNDS COMPRISING IMIDAZOLIUM GROUPS | BASF SE (DE) | 2012-09-27 | — | — | WO | disclosed |
| US-20050260238-A1 | Cosmetic compositions comprising wholly hydrophilic block copolymers and particular anti-fungal agents | L'OREAL (FR) | 2005-11-24 | — | — | US | disclosed |
| US-20040039030-A1 | Use of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis | HOECHST AKEENGESELLSCHAFT (DE) | 2004-02-26 | — | — | US | disclosed |
| US-20030086881-A1 | Antiinfective combinations and their use for the topical treatment of fungal infections of the toenails and fingernails | AVENTIS PHARMA DEUTSCHLAND GMBH | 2003-05-08 | — | — | US | disclosed |
| US-6455551-B1 | TREATING FUNGAL DISORDER CAUSED BY FLUCONAZOLE RESISTANT YEAST | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-09-24 | — | — | US | disclosed |
| US-6375939-B1 | ANTIDANDRUFF | L'OREAL (FR) | 2002-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050260238-A1 | Cosmetic compositions comprising wholly hydrophilic block copolymers and particular anti-fungal agents | SCLY, SUCLG1, POLR1C | GPR84 4613/4885 |
| US-20040039030-A1 | Use of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis | CYP24A1, CYP27B1, HSD3B1 | GPR84 2709/4885 |
| US-20180296459-A1 | COMPOSITIONS CONTAINING POLYMERIC, IONIC COMPOUNDS COMPRISING IMIDAZOLIUM GROUPS | PUF60, POLR1C, PICALM | GPR84 3656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.